Skip to main content

Table 1 Patient demographics and treatment characteristics by cardiomyopathy statusa

From: Electrocardiograms for cardiomyopathy risk stratification in children with anthracycline exposure

 

Cardiomyopathy (N = 115, 19.5%)

No Cardiomyopathy (N = 474, 80.5%)

P-value

Sex

 Male

73 (63.5)

249 (52.5)

0.03

 Female

42 (36.5)

225 (47.5)

 

Age at First Dose (years)

10.8 (4.9–15.1)

7.1 (3.4–12.9)

< 0.001

Race

 White

57 (50.4)

244 (51.6)

0.03

 Hispanic

32 (28.3)

160 (33.8)

 Black

18 (15.9)

34 (7.2)

 Other (including Asian)

6 (5.3)

35 (7.4)

 Unknown

2 (1.7)

1 (0.2)

Body Surface Area (m2)

1.20 (0.74–1.66)

0.88 (0.62–1.42)

< 0.001

Diagnosis

 Leukemia

57 (49.6)

253 (53.4)

0.08

 Solid Tumors

36 (31.3)

126 (26.6)

 Lymphoma

17 (14.8)

82 (17.3)

 Brain Tumors

1 (0.9)

10 (2.1)

 Multiple Diagnoses

4 (3.5)

3 (0.6)

Anthracycline Dose Total (mg/m2)

236.0 (153.0–329.0)

164.5 (92.0–232.0)

< 0.001

Cardiotoxic Radiation

 Yes

42 (36.5)

152 (32.1)

0.36

 No

73 (63.5)

322 (55.7)

Vital Status

 Alive

76 (66.1)

417 (88.0)

< 0.001

 Died

39 (33.9)

57 (12.0)

  1. aData presented as number of patients(%) or median (interquartile range)